About Iptacopan API
Therapeutic CategoryHaematology/Nephrology
CAS Number
1644670‑37‑0
API Technology
Small‑molecule synthetic API
Dose Form
口服固体/胶囊
Dr Reddy's Development Status
开发中
Mechanism of action
Iptacopan binds to complement factor B (FB), a key component of the alternative complement pathway.
This inhibits formation of the C3 convertase (C3bBb), thereby:
Reducing C3 cleavage and C3b generation
Preventing downstream formation of C5 convertase and the membrane attack complex (MAC)
By acting upstream (proximal) in the complement cascade, iptacopan controls:
C3b‑mediated extravascular hemolysis
Terminal complement‑mediated intravascular hemolysis
Importantly, it selectively blocks the alternative pathway, leaving the classical and lectin pathways intact to preserve host immune defense.
Indication
Approved indications (FDA / EMA):
Paroxysmal nocturnal hemoglobinuria (PNH) in adults
Reduction of proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression
Complement 3 glomerulopathy (C3G) to reduce proteinuria
Related APIs
Iptacopan
Haematology/Nephrology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
免责声明
本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。